AAAAAA

   
Results: 1-7 |
Results: 7
C-11 RADIOLABELING OF HALLUCINOGENIC PSILOCIN, A POTENTIAL RADIOLIGAND FOR STUDYING THE ROLE OF SEROTONIN RECEPTORS IN PSYCHOTIC SYMPTOM FORMATION
Authors: AMETAMEY S VOLLENWEIDER FX PATT J BOURQUIN D HASLER F BEER HF SCHUBIGER PA
Citation: S. Ametamey et al., C-11 RADIOLABELING OF HALLUCINOGENIC PSILOCIN, A POTENTIAL RADIOLIGAND FOR STUDYING THE ROLE OF SEROTONIN RECEPTORS IN PSYCHOTIC SYMPTOM FORMATION, Journal of labelled compounds & radiopharmaceuticals, 41(7), 1998, pp. 585-594
NEUTRALIZATION OF TNF BY LENERCEPT (TNFR55-IGG1,RO-45-2081) IN PATIENTS WITH RHEUMATOID-ARTHRITIS TREATED FOR 3 MONTHS - RESULTS OF A EUROPEAN PHASE-II TRIAL
Authors: SANDER O RAU R VANRIEL P VANDEPUTTE L HASLER F BAUDIN M LUDIN E MCAULIFFE T DICKINSON S KAHNY MR LESSLAUER W VANDERAUWERA P
Citation: O. Sander et al., NEUTRALIZATION OF TNF BY LENERCEPT (TNFR55-IGG1,RO-45-2081) IN PATIENTS WITH RHEUMATOID-ARTHRITIS TREATED FOR 3 MONTHS - RESULTS OF A EUROPEAN PHASE-II TRIAL, Arthritis and rheumatism, 39(9), 1996, pp. 1288-1288
SAFETY AND EFFICACY OF TNF NEUTRALIZATION BY LENERCEPT (TNFR55-IGG1, RO-45-2081) IN PATIENTS WITH RHEUMATOID-ARTHRITIS EXPOSED TO A SINGLE-DOSE
Authors: HASLER F VANDEPUTTE L DUMONT E KNEER J BOCK J DICKINSON S LESSLAUER W VANDERAUWERA P
Citation: F. Hasler et al., SAFETY AND EFFICACY OF TNF NEUTRALIZATION BY LENERCEPT (TNFR55-IGG1, RO-45-2081) IN PATIENTS WITH RHEUMATOID-ARTHRITIS EXPOSED TO A SINGLE-DOSE, Arthritis and rheumatism, 39(9), 1996, pp. 1291-1291
CHRONIC TNF NEUTRALIZATION (UP TO 1-YEAR) BY LENERCEPT (TNFR55-IGG1, RO-45-2081) IN PATIENTS WITH RHEUMATOID-ARTHRITIS - RESULTS OF AN OPEN-LABEL EXTENSION OF A DOUBLE-BLIND SINGLE-DOSE PHASE-I STUDY
Authors: HASLER F VANDEPUTTE L BAUDIN M LUDIN E DURRWELL L MCAULIFFE T VANDERAUWERA P
Citation: F. Hasler et al., CHRONIC TNF NEUTRALIZATION (UP TO 1-YEAR) BY LENERCEPT (TNFR55-IGG1, RO-45-2081) IN PATIENTS WITH RHEUMATOID-ARTHRITIS - RESULTS OF AN OPEN-LABEL EXTENSION OF A DOUBLE-BLIND SINGLE-DOSE PHASE-I STUDY, Arthritis and rheumatism, 39(9), 1996, pp. 1292-1292
ANALYSIS AND PHARMACOKINETICS OF GLYCYRRHIZIC ACID AND GLYCYRRHETINICACID IN HUMANS AND EXPERIMENTAL-ANIMALS
Authors: KRAHENBUHL S HASLER F KRAPF R
Citation: S. Krahenbuhl et al., ANALYSIS AND PHARMACOKINETICS OF GLYCYRRHIZIC ACID AND GLYCYRRHETINICACID IN HUMANS AND EXPERIMENTAL-ANIMALS, Steroids, 59(2), 1994, pp. 121-126
KINETICS AND DYNAMICS OF ORALLY-ADMINISTERED 18-BETA-GLYCYRRHETINIC ACID IN HUMANS
Authors: KRAHENBUHL S HASLER F FREY BM FREY FJ BRENNEISEN R KRAPF R
Citation: S. Krahenbuhl et al., KINETICS AND DYNAMICS OF ORALLY-ADMINISTERED 18-BETA-GLYCYRRHETINIC ACID IN HUMANS, The Journal of clinical endocrinology and metabolism, 78(3), 1994, pp. 581-585
DETERMINATION OF 18-BETA-GLYCYRRHETINIC ACID IN BIOLOGICAL-FLUIDS FROM HUMANS AND RATS BY SOLID-PHASE EXTRACTION AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
Authors: HASLER F KRAPF R BRENNEISEN R BOURQUIN D KRAHENBUHL S
Citation: F. Hasler et al., DETERMINATION OF 18-BETA-GLYCYRRHETINIC ACID IN BIOLOGICAL-FLUIDS FROM HUMANS AND RATS BY SOLID-PHASE EXTRACTION AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, Journal of chromatography. Biomedical applications, 620(1), 1993, pp. 73-82
Risultati: 1-7 |